enGene Therapeutics (ENGN) Balance Sheet: Assets & Liabilities

enGene Therapeutics (ENGN) Balance Sheet

As of Oct 31, 2025 (end of fiscal 2025), enGene Therapeutics reported total assets of $221.47M and total liabilities of $53.76M. Shareholders' equity was $167.71M, down 38.5% from $272.61M a year earlier. Total debt stood at $31.80M against $193.81M in cash and short-term investments, a net cash position of $162.02M. That puts debt-to-equity at 0.19, compared with 0.08 a year earlier.

enGene Therapeutics Balance Sheet Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Balance sheet showing assets, liabilities, and shareholders' equity for enGene Therapeutics Inc. (ENGN) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period ending	Oct 2025	Oct 2024	Oct 2023	Oct 2022	Oct 2021
Current Assets
Cash and Cash Equivalents	50.15	173.00	81.52	20.43	11.02
Short-Term Investments	143.66	65.33	0.08	0.07	0.00
Cash & Short-Term Investments	193.82	238.33	81.52	20.43	11.02
Accounts Receivable	2.23	0.33	2.34	1.34	1.62
Inventory	0.00	0.00	0.00	0.00	0.00
Other Current Assets	5.35	8.63	1.50	0.74	0.80
Total Current Assets	201.39	247.36	85.44	22.58	13.52
Non-Current Assets
Property, Plant & Equipment (Net)	10.19	2.91	0.59	0.39	0.57
Long-Term Investments	8.52	59.53	0.07	131.53	129.67
Other Non-Current Assets	1.36	1.37	0.93	0.94	0.94
Total Non-Current Assets	20.08	63.81	1.52	131.53	129.88
Total Assets	221.47	311.17	86.96	23.91	15.03
Current Liabilities
Accounts Payable	6.69	1.41	1.16	0.72	1.00
Short-Term Debt	10.02	0.70	0.56	1.27	1.05
Current Portion of Long-Term Debt	8.00	0.70	0.56	1.27	1.05
Accrued Liabilities	10.63	8.43	3.54	3.12	1.09
Other Current Liabilities	15.28	0.23	0.11	0.87	0.02
Total Current Liabilities	31.98	14.66	5.26	5.10	3.22
Non-Current Liabilities
Long-Term Debt	21.78	22.47	9.22	27.05	2.45
Other Non-Current Liabilities	0.00	0.00	0.00	15.25	0.60
Total Non-Current Liabilities	21.78	23.90	9.22	42.30	3.73
Total Liabilities	53.76	38.56	14.47	35.95	6.26
Stockholders' Equity
Common Stock	513.28	509.81	259.37	16.39	16.36
Retained Earnings	-372.03	-254.73	-199.59	-99.67	-75.21
Accumulated Other Comprehensive Income	-0.89	-1.42	-1.02	-1.02	-2.18
Additional Paid-in Capital	27.35	18.95	13.72	0.00	0.00
Shares Outstanding	52.02	50.98	23.20	23.20	-
Total Stockholders' Equity	167.71	272.61	72.49	-12.04	8.76
Total Liabilities & Equity	221.47	311.17	86.96	132.04	131.45

Source: Company financial statements from annual and quarterly filings. Data as of Jul 31, 2026. Data sources and methodology

Frequently Asked Questions About enGene Therapeutics Balance Sheet

How much debt does enGene Therapeutics have?

enGene Therapeutics had total debt of $31.80M as of Oct 31, 2025, against $193.81M in cash and short-term investments. Its debt-to-equity ratio was 0.19. Total debt was $23.17M a year earlier.

What are enGene Therapeutics's total assets?

enGene Therapeutics reported total assets of $221.47M as of Oct 31, 2025, down 28.8% from $311.17M a year earlier. Total liabilities were $53.76M.

What is enGene Therapeutics's shareholders' equity?

enGene Therapeutics's shareholders' equity was $167.71M as of Oct 31, 2025, or about $3.22 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition